Syndax switches first-line plans
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
